BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36374555)

  • 21. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
    Escudier B; Motzer RJ; Tannir NM; Porta C; Tomita Y; Maurer MA; McHenry MB; Rini BI
    Eur Urol; 2020 Apr; 77(4):449-453. PubMed ID: 31732098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma.
    Koh Y; Nakano K; Katayama K; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Imamura R; Yamaguchi R; Imoto S; Shiotsu Y; Nonomura N; Uemura M
    Int J Urol; 2022 May; 29(5):462-469. PubMed ID: 35184335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptional Profiling Reveals Kidney Neutrophil Heterogeneity in Both Healthy People and ccRCC Patients.
    Meng Y; Cai K; Zhao J; Huang K; Ma X; Song J; Liu Y
    J Immunol Res; 2021; 2021():5598627. PubMed ID: 33791390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
    Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma.
    Bando Y; Furukawa J; Okamura Y; Hara T; Terakawa T; Nakano Y; Fujisawa M
    Anticancer Res; 2022 Feb; 42(2):973-979. PubMed ID: 35093897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
    Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
    Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
    Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
    Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab.
    Lyu C; Stadlbauer B; Wang L; Buchner A; Pohla H
    Front Immunol; 2023; 14():1186388. PubMed ID: 37622107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
    Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
    Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma.
    Kubo T; Sugawara T; Shinkawa T; Kurisu T; Kouzen N; Tanaka T; Fukuta F; Yamasaki K; Sugita S; Matsuo K; Morita R; Hirohashi Y; Tsukahara T; Kanaseki T; Hasegawa T; Masumori N; Torigoe T
    Immunol Med; 2021 Jun; 44(2):136-141. PubMed ID: 32634346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation.
    Schvartsman G; Carneiro APCD; Filippi RZ; Rao P; Msaouel P
    Clin Genitourin Cancer; 2019 Aug; 17(4):315-318. PubMed ID: 31213412
    [No Abstract]   [Full Text] [Related]  

  • 35. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma.
    Gao X; McDermott DF
    Expert Opin Biol Ther; 2018 Sep; 18(9):947-957. PubMed ID: 30124333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
    Au L; Hatipoglu E; Robert de Massy M; Litchfield K; Beattie G; Rowan A; Schnidrig D; Thompson R; Byrne F; Horswell S; Fotiadis N; Hazell S; Nicol D; Shepherd STC; Fendler A; Mason R; Del Rosario L; Edmonds K; Lingard K; Sarker S; Mangwende M; Carlyle E; Attig J; Joshi K; Uddin I; Becker PD; Sunderland MW; Akarca A; Puccio I; Yang WW; Lund T; Dhillon K; Vasquez MD; Ghorani E; Xu H; Spencer C; López JI; Green A; Mahadeva U; Borg E; Mitchison M; Moore DA; Proctor I; Falzon M; Pickering L; Furness AJS; Reading JL; Salgado R; Marafioti T; Jamal-Hanjani M; ; Kassiotis G; Chain B; Larkin J; Swanton C; Quezada SA; Turajlic S;
    Cancer Cell; 2021 Nov; 39(11):1497-1518.e11. PubMed ID: 34715028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
    Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
    J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
    Hagiwara M; Fushimi A; Matsumoto K; Oya M
    Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.
    Motzer RJ; Choueiri TK; McDermott DF; Powles T; Vano YA; Gupta S; Yao J; Han C; Ammar R; Papillon-Cavanagh S; Saggi SS; McHenry MB; Ross-Macdonald P; Wind-Rotolo M
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35304405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.